论文部分内容阅读
目的 :观察左氟沙星 (LVLX)治疗初治涂阳煤工尘肺结核的临床疗效及安全性。方法 :将 70例初治涂阳煤工尘肺结核病人随机分为两组。治疗组 3 5例 ,用 3HRVE/6HRE方案化疗 ;对照组 3 5例 ,用 3HRZE/6HRE方案化疗。结果 :两组满疗程时痰菌阴转率分别是 97 1%和 10 0 0 % (P >0 0 5 ) ;病灶吸收好转率分别是 97 0 %和 93 9% (P >0 0 5 )。药物不良反应治疗组轻于对照组。结论 :含LVLX方案治疗初治涂阳煤工尘肺结核近期疗效满意 ,对不能耐受PZA口服的病人 ,可用LVLX代替PZA。
Objective: To observe the clinical efficacy and safety of levofloxacin (LVLX) in the treatment of primary smear-positive pneumoconiosis tuberculosis. Methods: Seventy patients with newly diagnosed smear-positive pneumoconiosis tuberculosis were randomly divided into two groups. The treatment group 35 cases, with 3HRVE / 6HRE regimen chemotherapy; control group 35 cases, with 3HRZE / 6HRE regimen chemotherapy. Results: The rate of sputum negative conversion was 97 1% and 100%, respectively (P 0 05). The recovery rates of the lesions were 97 0% and 93 9%, respectively (P 0 05) . Adverse drug reaction treatment group lighter than the control group. CONCLUSION: LVLX regimen is satisfactory for the treatment of newly-diagnosed smear-positive pneumoconiosis tuberculosis. For patients who can not tolerate oral PZA, LVLX may be used instead of PZA.